Hologic (NASDAQ:HOLX) Stock Rating Upgraded by Wall Street Zen

Key Points

• Hologic's stock was upgraded from a "hold" to a "buy" rating by Wall Street Zen, with a consensus rating of "Moderate Buy" and an average price target of $79.38.
• The company reported a quarterly EPS of $1.08, surpassing analysts' expectations, with revenues of $1.02 billion, indicating a year-over-year revenue growth of 1.2%.
• Institutional investors own approximately 94.73% of Hologic's shares, with significant recent stake acquisitions from various hedge funds.

Hologic (NASDAQ:HOLX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday.

A number of other equities research analysts also recently commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Stephens restated an "overweight" rating and issued a $78.00 target price on shares of Hologic in a report on Thursday, September 18th. Finally, Argus boosted their target price on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $79.38.

Hologic Stock Performance

Shares of HOLX opened at $67.29 on Tuesday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.97 billion, a P/E ratio of 27.92, a PEG ratio of 2.40 and a beta of 0.57. The company has a 50-day moving average of $66.53 and a two-hundred day moving average of $62.77. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts predict that Hologic will post 4.28 EPS for the current fiscal year.

Institutional Trading of Hologic

Institutional investors and hedge funds have recently modified their holdings of the business. Chung Wu Investment Group LLC bought a new stake in shares of Hologic during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after buying an additional 273 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Hologic during the 2nd quarter worth about $33,000. Zions Bancorporation National Association UT bought a new stake in shares of Hologic during the 1st quarter worth about $34,000. Finally, Cromwell Holdings LLC boosted its position in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.